jama glp-1 I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know?

Postpartum prescription of #GLP-1RAs in Denmark increased between 2018 and 2024, with #semaglutide accounting for most prescriptions since 2023. Most users had #overweight or #obesity, and only 23% had a #diabetes diagnosis

25.63

★★★★☆4.8 (126)

Did you know JAMA (Journal of the American Medical Association) released a free Patient Page entitled: I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know? Check it out here: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle

26.70

★★★★★4.9 (98)

SocietyGIM Antiobesity medications may improve weight loss and health outcomes by altering biological processes related to appetite. ➡️ This Review summarizes the efficacy and safety of #AOMs. https://t.co/bZYudlPtmn #GLP1 #SGIM25

24.91

★★★★★5.0 (157)

From JAMA: #GLP-1 receptor agonist exposure with discontinuation before or during early #pregnancy was associated with greater gestational weight gain and increased risk of preterm delivery, gestational #diabetes, and hypertensive disorders. https://ja

27.42

★★★★★4.7 (84)

JAMA

20.99

★★★★★4.9 (203)

Bariatric Surgery vs. GLP-1 Injections

24.17

★★★★★5.0 (176)

📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no

21.61

★★★★★4.8 (132)